Cytokinetics (CYTK) insider schedules 24,000-share option-related stock sale

Rhea-AI Filing Summary

Cytokinetics, Incorporated insider Andrew Callos filed to sell common stock. The notice lists a planned sale of 24,000 shares of common stock on July 30, 2026, to be effected through Morgan Stanley Smith Barney LLC in connection with an exercise of stock options.

The filing also details prior Rule 10b5-1 plan sales of common stock over the past three months, including transactions on May 1, 2026, May 5, 2026, June 1, 2026, and June 30, 2026, with share counts and aggregate proceeds disclosed for each sale.

Key Figures

Planned shares to be sold: 24,000 shares Planned sale date: 07/30/2026 June 30, 2026 sale: 15,000 shares for $1,287,069.00 +3 more

6 metrics

Planned shares to be sold 24,000 shares Common stock sale associated with exercise of stock options on July 30, 2026

Planned sale date 07/30/2026 Date of proposed 24,000-share sale of common stock

June 30, 2026 sale 15,000 shares for $1,287,069.00 10b5-1 sale of common stock on June 30, 2026

June 1, 2026 sale 15,000 shares for $1,111,237.50 10b5-1 sale of common stock on June 1, 2026

May 5, 2026 sale 11,333 shares for $875,474.25 10b5-1 sale of common stock on May 5, 2026

May 1, 2026 sale 15,857 shares for $1,030,705.00 10b5-1 sale of common stock on May 1, 2026

Key Terms

Form 144, Exercise of Stock Options, 10b5-1 Sales

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Exercise of Stock Options financial

"Common | 07/30/2026 | Exercise of Stock Options | Issuer"

10b5-1 Sales regulatory

"10b5-1 Sales for ANDREW CALLOS 350 OYSTER POINT BOULEVARD"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/30/2026 - 04:23 PM Accepted by SEC EDGAR 07/30/2026 - 04:22 PM Learn about SEC filing dates

FAQ

What stock sale is Andrew Callos planning according to the CYTK Form 144?

Andrew Callos plans to sell 24,000 shares of Cytokinetics common stock on July 30, 2026. The sale is tied to an exercise of stock options and will be executed through Morgan Stanley Smith Barney LLC.

How many CYTK shares did Andrew Callos sell on June 30, 2026?

On June 30, 2026, Andrew Callos sold 15,000 shares of Cytokinetics common stock for aggregate proceeds of $1,287,069.00 under a Rule 10b5-1 trading plan.

What CYTK stock sales did Andrew Callos make on June 1, 2026?

On June 1, 2026, Andrew Callos sold 15,000 shares of Cytokinetics common stock. The filing reports total proceeds of $1,111,237.50, and identifies the transactions as 10b5-1 sales.

What earlier CYTK sales are disclosed for Andrew Callos in May 2026?

In May 2026, Andrew Callos sold 11,333 shares on May 5 for $875,474.25 and 15,857 shares on May 1 for $1,030,705.00, each described as 10b5-1 sales of Cytokinetics common stock.

What is the purpose of the CYTK Form 144 filed by Andrew Callos?

The Form 144 gives notice of a proposed sale of 24,000 shares of Cytokinetics common stock on July 30, 2026, in connection with an exercise of stock options, and lists related 10b5-1 sales during the prior three months.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	24000	1881240.00	124432565	07/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/30/2026	Exercise of Stock Options	Issuer			24000	07/30/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ANDREW CALLOS 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	06/30/2026	15000	1287069.00
10b5-1 Sales for ANDREW CALLOS 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	06/01/2026	15000	1111237.50
10b5-1 Sales for ANDREW CALLOS 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	05/05/2026	11333	875474.25
10b5-1 Sales for ANDREW CALLOS 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080	Common	05/01/2026	15857	1030705.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)